Medical Affairs Outsourcing Market Sees Growth as Moderna Strengthens Commercial Leadership

Moderna is planning to launch three new products from 2027 through 2028 to further accelerate its business. For this purpose, the company hired Novartis, Ester Banque as its chief commercial officer to oversee each of the company’s three divisions: R&D, commercial, and manufacturing.

Moderna Plans to ensure Strategic Alignment across the Business

This leading company aims to strengthen enterprise execution and boost the company’s delivery of novel medicines to patients across the world. A collaborative experience of around 25 years from Novartis and Bristol Myers Squibb will establish Moderna’s commercial organization and guide the execution of its product launches.

However, Moderna is expected to begin commercialization of a COVID shot and a combination flu vaccine in the next two years. It is also expected that the company will launch vaccines for seasonal flu and norovirus, alongside their coming approvals.

According to Precedence Research, the medical affairs outsourcing Market size was calculated at USD 2.08 billion in 2025 and is predicted to increase from USD 2.23 billion in 2026 to approximately USD 4.12 billion by 2035, expanding at a CAGR of 7.07% from 2026 to 2035, due to the biotechnology boom, resource optimization, high-burden therapeutic areas, and digital and technological integration. Outsourcing introduces operational flexibility and allows companies to convert fixed overhead costs into variable costs.

Industry Impact and Market Outlook

The medical affairs outsourcing market is dominated by specialized life sciences service providers and major global contract research organizations (CROs). The global contract research organizations are IQVIA Holdings Inc., ICON Plc, Syneos Health, Parexel International Corporation, Thermo Fisher Scientific, and Medpace Holdings. Moreover, the specialized commercialization and healthcare communication firms are Indegene Inc., EVERSANA, Inizio Medical, The Medical Affairs Company, and OPEN Health. On the other hand, the global analytical and regulatory support firms are WuXi AppTec, SGS S.A., and Certara. The principal deliverables of these top companies are peer-to-peer scientific communication, clinical trial reports, literature reviews, etc. The leaders, like IQVIA, introduced AI-powered life science agents, an agentic cloud ecosystem, and real-world evidence platforms. ICON Plc has provided an operational AI portfolio, decentralized clinical trial platforms, and regulatory writing and publishing hubs.